| 1 |
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Soonmyung Paik, Steven Shak, Gong Tang et al. · New England Journal of Medicine
Open access |
10 Dec 2004 |
6,414 |
| 2 |
Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer
Bernard Fisher, Stewart Anderson, John Bryant et al. · New England Journal of Medicine
Open access |
16 Oct 2002 |
6,293 |
| 3 |
Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
Bernard Fisher, Joseph P. Costantino, Donald Lawrence Wickerham et al. · JNCI Journal of the National Cancer Institute
Open access |
16 Sep 1998 |
5,532 |
| 4 |
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Edward H. Romond et al. · New England Journal of Medicine
Open access |
20 Oct 2005 |
5,398 |
| 5 |
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al. · The Lancet
Open access |
13 Feb 2014 |
4,858 |
| 6 |
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff, M. Elizabeth Hammond, David G. Hicks et al. · Journal of Clinical Oncology
|
7 Oct 2013 |
4,103 |
| 7 |
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Gϋnter von Minckwitz et al. · New England Journal of Medicine
Open access |
5 Dec 2018 |
2,689 |
| 8 |
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Joseph A. Sparano et al. · New England Journal of Medicine
Open access |
3 Jun 2018 |
2,447 |
| 9 |
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Bernard Fisher, John Bryant, Norman Wolmark et al. · Journal of Clinical Oncology
|
Aug 1998 |
2,206 |
| 10 |
Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial
David N. Krag, Stewart Anderson, Thomas B. Julian et al. · The Lancet Oncology
Open access |
Oct 2010 |
1,949 |
| 11 |
Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer
Andrew N.J. Tutt et al. · New England Journal of Medicine
Open access |
3 Jun 2021 |
1,744 |
| 12 |
Eight-Year Results of a Randomized Clinical Trial Comparing Total Mastectomy and Lumpectomy with or without Irradiation in the Treatment of Breast Cancer
Bernard Fisher, Carol K. Redmond, ROGER POISSON et al. · New England Journal of Medicine
|
30 Mar 1989 |
1,601 |
| 13 |
A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive Tumors
Bernard Fisher et al. · New England Journal of Medicine
|
23 Feb 1989 |
1,485 |
| 14 |
Reanalysis and Results after 12 Years of Follow-up in a Randomized Clinical Trial Comparing Total Mastectomy with Lumpectomy with or without Irradiation in the Treatment of Breast Cancer
Bernard Fisher, Stewart Anderson, Carol K. Redmond et al. · New England Journal of Medicine
Open access |
30 Nov 1995 |
1,475 |
| 15 |
Twenty-Five-Year Follow-up of a Randomized Trial Comparing Radical Mastectomy, Total Mastectomy, and Total Mastectomy Followed by Irradiation
Bernard Fisher, Jong‐Hyeon Jeong, Stewart Anderson et al. · New England Journal of Medicine
Open access |
22 Aug 2002 |
1,406 |
| 16 |
Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
Bernard Fisher, Joseph P. Costantino, Donald Lawrence Wickerham et al. · JNCI Journal of the National Cancer Institute
|
15 Nov 2005 |
1,343 |
| 17 |
Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18
Norman Wolmark, J. Wang, Eleftherios Mamounas et al. · JNCI Monographs
Open access |
Dec 2001 |
1,321 |
| 18 |
Nanomaterials for Theranostics: Recent Advances and Future Challenges
Eun‐Kyung Lim, Taekhoon Kim, Soonmyung Paik et al. · Chemical Reviews
ReviewOpen access |
25 Nov 2014 |
1,236 |
| 19 |
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M Simon, Seungmok Paik, Daniel F.C. Hayes · JNCI Journal of the National Cancer Institute
Open access |
8 Oct 2009 |
1,047 |
| 20 |
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
Bernard Fisher, James J. Dignam, Norman Wolmark et al. · The Lancet
|
Jun 1999 |
1,045 |
| 21 |
Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update
Bernard Fisher, Madeline Bauer, Donald Lawrence Wickerham et al. · Cancer
|
Nov 1983 |
1,043 |
| 22 |
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Stephen R.D. Johnston et al. · Journal of Clinical Oncology
Open access |
20 Sep 2020 |
1,037 |
| 23 |
Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
Harry D. Bear, Stewart Anderson, Roy E. Smith et al. · Journal of Clinical Oncology
|
11 Apr 2006 |
951 |
| 24 |
Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03
Mark S. Roh, Linda H. Colangelo, Michael J. O’Connell et al. · Journal of Clinical Oncology
Open access |
21 Sep 2009 |
946 |
| 25 |
Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17.
Bernard Fisher, James J. Dignam, Norman Wolmark et al. · Journal of Clinical Oncology
|
Feb 1998 |
899 |
| 26 |
Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive Tumors
Bernard Fisher et al. · JNCI Journal of the National Cancer Institute
|
6 Nov 1996 |
871 |
| 27 |
Lumpectomy Compared with Lumpectomy and Radiation Therapy for the Treatment of Intraductal Breast Cancer
Bernard Fisher, Joseph P. Costantino, Carol K. Redmond et al. · New England Journal of Medicine
|
3 Jun 1993 |
832 |
| 28 |
Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31
Elizabeth Tan-Chiu, Greg Yothers, Edward H. Romond et al. · Journal of Clinical Oncology
|
28 Oct 2005 |
818 |
| 29 |
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourina
Shona A. Hendry et al. · Advances in Anatomic Pathology
Open access100 authors |
2 Aug 2017 |
816 |
| 30 |
Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS
Irene Wapnir, James J. Dignam, Bernard Fisher et al. · JNCI Journal of the National Cancer Institute
Open access |
11 Mar 2011 |
789 |
| 31 |
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl, Joyce O’Shaughnessy, Michael Untch et al. · The Lancet Oncology
|
28 Feb 2018 |
781 |
| 32 |
Validation Studies for Models Projecting the Risk of Invasive and Total Breast Cancer Incidence
Joseph P. Costantino, Mitchell H. Gail, D. Pee et al. · JNCI Journal of the National Cancer Institute
Open access |
15 Sep 1999 |
773 |
| 33 |
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research
Shona A. Hendry et al. · Advances in Anatomic Pathology
Open access100 authors |
2 Aug 2017 |
739 |
| 34 |
Tamoxifen, Radiation Therapy, or Both for Prevention of Ipsilateral Breast Tumor Recurrence After Lumpectomy in Women With Invasive Breast Cancers of One Centimeter or Less
Bernard Fisher, John Bryant, James J. Dignam et al. · Journal of Clinical Oncology
|
11 Oct 2002 |
697 |
| 35 |
The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03.
Norman Wolmark, Howard E. Rockette, Bernard Fisher et al. · Journal of Clinical Oncology
|
Oct 1993 |
689 |
| 36 |
Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials
Daniel J. Sargent, Alberto Felice Sobrero, Axel F. Grothey et al. · Journal of Clinical Oncology
Open access |
5 Jan 2009 |
687 |
| 37 |
Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses
Greg Yothers, Michael J. O’Connell, Carmen Joseph Allegra et al. · Journal of Clinical Oncology
Open access |
23 Aug 2011 |
670 |
| 38 |
Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials
Joseph A. Sparano, Soonmyung Paik · Journal of Clinical Oncology
|
7 Feb 2008 |
660 |
| 39 |
Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20
Eleftherios P. Mamounas, Gong Tang, Bernard Fisher et al. · Journal of Clinical Oncology
Open access |
11 Jan 2010 |
657 |
| 40 |
erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer
Soonmyung Paik, John Bryant, Chanheun Park et al. · JNCI Journal of the National Cancer Institute
|
16 Sep 1998 |
656 |
| 41 |
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer
Victor G. Vogel et al. · Cancer Prevention Research
Open access |
19 Apr 2010 |
646 |
| 42 |
Five Versus More Than Five Years of Tamoxifen for Lymph Node-Negative Breast Cancer: Updated Findings From the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial
Bernard Fisher, J Dignam, Jennifer Bryant et al. · JNCI Journal of the National Cancer Institute
|
2 May 2001 |
639 |
| 43 |
Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
Bernard Fisher, Ann M. Brown, Nikolay V. Dimitrov et al. · Journal of Clinical Oncology
|
Sep 1990 |
629 |
| 44 |
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
Stephen R.D. Johnston et al. · The Lancet Oncology
Open access |
6 Dec 2022 |
603 |
| 45 |
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
Joseph A. Sparano et al. · New England Journal of Medicine
Open access |
3 Jun 2019 |
564 |
| 46 |
Significance of ipsilateral breast tumour recurrence after lumpectomy
Bernard Fisher, Stewart Anderson, Edwin R. Fisher et al. · The Lancet
|
Aug 1991 |
560 |
| 47 |
DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
Frank A. Sinicrope, Nathan R. Foster, Stephen N. Thibodeau et al. · JNCI Journal of the National Cancer Institute
Open access |
19 May 2011 |
540 |
| 48 |
Comparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes' B Versus Dukes' C Colon Cancer: Results From Four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03, and C-04)
Eleftherios P. Mamounas, Samuel Wieand, Norman Wolmark et al. · Journal of Clinical Oncology
|
May 1999 |
533 |
| 49 |
Randomized Trial of Postoperative Adjuvant Chemotherapy With or Without Radiotherapy for Carcinoma of the Rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02
Norman Wolmark · JNCI Journal of the National Cancer Institute
Open access |
Mar 2000 |
532 |
| 50 |
Tamoxifen and Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Positive Breast Cancer
Bernard Fisher, James J. Dignam, Birol Emir et al. · JNCI Journal of the National Cancer Institute
|
19 Nov 1997 |
527 |